Moderna Inc. has received approval from the US Food and Drug Administration for its RSV vaccine in older adults, marking a significant milestone for the biotech company as it expands beyond its Covid-19 shot. The vaccine, named mRESVIA, is targeted at adults aged 60 and older and is designed to combat respiratory syncytial virus, a flu-like illness that poses a serious threat to elderly adults and babies.
The approval comes at a crucial time for Moderna, which has been looking to diversify its product portfolio and reduce its reliance on Covid-19 vaccines. The company’s stock price had taken a hit as the world transitions away from the pandemic, making the approval of the RSV vaccine a much-needed boost.
Despite facing a slight decline in effectiveness during a follow-up analysis, Moderna’s RSV shot is expected to compete with products from GSK and Pfizer, which generated significant sales last year. Moderna’s unique advantage lies in the convenience of its pre-filled syringe, making it easier for pharmacists to administer compared to other options on the market.
With the RSV market for seniors projected to reach $11 billion by 2032, Moderna is poised to capture a significant share alongside GSK and Pfizer. The company anticipates having mRESVIA available in the US for the upcoming fall respiratory virus season, providing a timely solution for older adults at risk of RSV.
As advisers to the US Centers for Disease Control and Prevention prepare to make recommendations on this year’s RSV shots, Moderna’s approval signals a new chapter in the company’s growth and innovation in the biotech industry.
